We are live on ! Find out more
CM

Crestline Management Portfolio holdings

AUM $53.5M
1-Year Est. Return 80.67%
This Fund
S&P 500
This Quarter Est. Return
+32.35%
1 Year Est. Return
+80.67%
3 Year Est. Return
+80.2%
5 Year Est. Return
+49.87%
10 Year Est. Return
+446.13%
AUM
$53.5M
AUM Growth
+$7.21M
Cap. Flow
-$6.16M
Cap. Flow %
-11.53%
Top 10 Hldgs %
100%
Holding
3
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 96.83%
2 Technology 3.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DNLI icon
1
Denali Therapeutics
DNLI
$3.84B
$49.1M 91.9%
1,910,732
-300,000
-14% -$6.16M
SANA icon
2
Sana Biotechnology
SANA
$1.18B
$2.64M 4.93%
755,736
EGHT icon
3
8x8 Inc
EGHT
$287M
$1.69M 3.17%
990,850

Similar funds

Crestline Management's Q2 2026 Portfolio in Review

As of Q2 2026, Crestline Management held 3 positions worth $53.5M, up 16% from $46.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Crestline Management withdrew a net $6.16M in Q2 2026, reducing 1 holding. Its largest reduction was Denali Therapeutics, cutting an estimated $6.16M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Technology.

  • Crestline Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $6.16M.
  • Crestline Management's ten largest holdings make up 100% of its $53.5M portfolio in Q2 2026.
  • Crestline Management opened 0 new positions and closed 0 in Q2 2026.
  • Crestline Management's portfolio value rose 16% quarter-over-quarter to $53.5M.

Based on Crestline Management's 13F filing for Q2 2026, filed 14 Aug 2026.